Alfacalcidol

Evidence Level: L5

Predicted Indications: 3

Alfacalcidol

Pharmacist Assessment Report

One-Sentence Summary

Alfacalcidol is an active vitamin D analog. The TxGNN model predicts it may be effective for craniofacial conodysplasia, an ultra-rare skeletal dysplasia. This prediction rests on the model alone, with 0 clinical trials and 0 publications supporting it.

Quick Overview

Item	Content
Original Indication	Hyperparathyroidism, osteitis fibrosa, hypoparathyroidism, renal osteodystrophy (relations recorded in the knowledge graph; no licence indication text is available)
Predicted New Indication	Craniofacial conodysplasia
TxGNN Prediction Score	0.9955
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 6 of 6)
Number of DINs	6 (marketed: 6)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available. Alfacalcidol is a pre-activated (1-alpha-hydroxylated) vitamin D analog. It is converted in the liver to calcitriol, the active form of vitamin D. It regulates calcium and phosphate balance and bone mineralization.

A link to a skeletal disorder such as craniofacial conodysplasia is biologically plausible, but it is speculative and unvalidated. No study in the data compiled for this report examines this disease. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Two other model predictions were also reviewed, but neither changes this assessment. Acromesomelic dysplasia, Campailla Martinelli type, also has no supporting studies. Renal tubular acidosis has only case reports describing alfacalcidol used within regimens for osteomalacia caused by the condition. That evidence concerns a complication, not the acidification defect itself.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

All 6 authorisations are valid single-ingredient products. Dosage form and approved-indication text are not available in the data compiled for this report.

DIN	Product Name	Status
02533324	SANDOZ ALFACALCIDOL	Valid
02533316	SANDOZ ALFACALCIDOL	Valid
02240329	ONE-ALPHA	Valid
02242502	ONE-ALPHA	Valid
00474525	ONE-ALPHA	Valid
00474517	ONE-ALPHA	Valid

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the TxGNN model score, with no clinical trials, no publications and no validated mechanism for craniofacial conodysplasia. The evidence level is L5. Alfacalcidol is marketed in Canada, but the data compiled for this report contain no licence indication text or safety label data.

To proceed, the following is needed:

Health Canada product monograph warnings, contraindications and approved indications, which are required before any safety screening
Mechanism of action data for alfacalcidol
A literature and registry search for any direct study of vitamin D analogs in craniofacial conodysplasia
A mechanistic rationale linking vitamin D signalling to the pathology of this dysplasia
If the renal tubular acidosis prediction is pursued, a separate evaluation of RTA-associated osteomalacia, with monitoring for hypercalciuria and nephrocalcinosis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.